Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
INSM

INSM - Insmed Inc Stock Price, Fair Value and News

$155.89-6.75 (-4.15%)
Market Closed

14/100

INSM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

14/100

INSM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$124.97

Target 3M

$140.59

Target 6M

$132.78

INSM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INSM Price Action

Last 7 days

-0.3%

Last 30 days

-11.6%

Last 90 days

-19.7%

Trailing 12 Months

98.7%

INSM RSI Chart

INSM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INSM Valuation

Market Cap

33.2B

Price/Earnings (Trailing)

-28.08

Price/Sales (Trailing)

74.37

EV/EBITDA

-30.04

Price/Free Cashflow

-36.69

INSM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$124.97

Target 3M

$140.59

Target 6M

$132.78

INSM Fundamentals

INSM Revenue

Revenue (TTM)

447.0M

Rev. Growth (Yr)

52.36%

Rev. Growth (Qtr)

32.52%

INSM Earnings

Earnings (TTM)

-1.2B

Earnings Growth (Yr)

-67.79%

Earnings Growth (Qtr)

-15.03%

INSM Profitability

EBT Margin

-263.77%

Return on Equity

-125.2%

Return on Assets

-50.15%

Free Cashflow Yield

-2.73%

INSM Investor Care

Shares Dilution (1Y)

19.21%

Diluted EPS (TTM)

-6.17

INSM Alerts

  • 6 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025381.0M398.1M447.0M0
2024315.5M328.6M343.0M363.7M
2023257.5M269.5M280.8M305.2M
2022201.4M221.2M242.2M245.4M
2021167.8M170.6M173.8M188.5M
2020151.4M163.9M168.7M164.4M
201937.2M64.5M100.6M136.5M
20183.5M6.1M8.5M17.3M
2017588.0K593.0K781.0K1.6M
2016408.0K504.0K567.0K604.0K
20154.0M2.1M178.0K261.0K
20149.6M7.7M5.8M0
20135.3M7.4M9.4M11.5M
20123.2M000
20116.6M5.7M4.3M4.4M
201009.2M8.1M6.9M
200900010.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Insmed Inc

INSM
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis, cystic fibrosis, and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
 CEO
 WEBSITEinsmed.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES736

Insmed Inc Frequently Asked Questions

INSM is the stock ticker symbol of Insmed Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Insmed Inc is 33.25 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check INSM's fair value in chart for subscribers.

The fair value guage provides a quick view whether INSM is over valued or under valued. Whether Insmed Inc is cheap or expensive depends on the assumptions which impact Insmed Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INSM.

As of Wed Jan 28 2026, INSM's PE ratio (Price to Earnings) is -28.08 and Price to Sales (PS) ratio is 74.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INSM PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Insmed Inc has provided 0.28 (multiply by 100 for percentage) rate of return.